126 related articles for article (PubMed ID: 9161116)
1. Constructing health state preference values from descriptive quality of life outcomes: mission impossible?
Chancellor JV; Coyle D; Drummond MF
Qual Life Res; 1997 Mar; 6(2):159-68. PubMed ID: 9161116
[TBL] [Abstract][Full Text] [Related]
2. Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593. Eastern Cooperative Oncology Group.
Auchter RM; Scholtens D; Adak S; Wagner H; Cella DF; Mehta MP
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1199-206. PubMed ID: 11483329
[TBL] [Abstract][Full Text] [Related]
3. Quality of life of lung cancer patients in a randomized clinical trial evaluated by a psychosocial well-being questionnaire.
Kaasa S; Mastekaasa A; Naess S
Acta Oncol; 1988; 27(4):335-42. PubMed ID: 2849460
[TBL] [Abstract][Full Text] [Related]
4. Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer.
van den Hout WB; Kramer GW; Noordijk EM; Leer JW
J Natl Cancer Inst; 2006 Dec; 98(24):1786-94. PubMed ID: 17179480
[TBL] [Abstract][Full Text] [Related]
5. Symptom experiences and health-related quality of life among non-small cell lung cancer patients participating in clinical trials.
Lee K; Oh EG; Kim S; Kim SW
J Clin Nurs; 2019 Jun; 28(11-12):2111-2123. PubMed ID: 30667122
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported short-term and long-term physical and psychologic symptoms: results of the continuous hyperfractionated accelerated [correction of acclerated] radiotherapy (CHART) randomized trial in non-small-cell lung cancer. CHART Steering Committee.
Bailey AJ; Parmar MK; Stephens RJ
J Clin Oncol; 1998 Sep; 16(9):3082-93. PubMed ID: 9738579
[TBL] [Abstract][Full Text] [Related]
7. Survey of the Administration of quality of life (QL) questionnaires in three multicentre randomised trials in cancer. The Medical Research Council Lung Cancer Working Party the CHART Steering Committee.
Hopwood P; Harvey A; Davies J; Stephens RJ; Girling DJ; Gibson D; Parmar MK
Eur J Cancer; 1998 Jan; 34(1):49-57. PubMed ID: 9624237
[TBL] [Abstract][Full Text] [Related]
8. Mapping functions in health-related quality of life: mapping from the Achilles Tendon Rupture Score to the EQ-5D.
Hua AY; Westin O; Hamrin Senorski E; Svantesson E; Grassi A; Zaffagnini S; Samuelsson K; Svensson M
Knee Surg Sports Traumatol Arthrosc; 2018 Oct; 26(10):3083-3088. PubMed ID: 29691617
[TBL] [Abstract][Full Text] [Related]
9. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
Griebsch I; Coast J; Brown J
Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
[TBL] [Abstract][Full Text] [Related]
10. Quality of life assessment in patients with carcinoma of the lung.
Feld R
Chest; 1989 Jul; 96(1 Suppl):105S-107S. PubMed ID: 2544353
[No Abstract] [Full Text] [Related]
11. Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics.
Trippoli S; Vaiani M; Lucioni C; Messori A
Pharmacoeconomics; 2001; 19(8):855-63. PubMed ID: 11596837
[TBL] [Abstract][Full Text] [Related]
12. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.
Reck M; Brahmer J; Bennett B; Taylor F; Penrod JR; DeRosa M; Dastani H; Spigel DR; Gralla RJ
Eur J Cancer; 2018 Oct; 102():23-30. PubMed ID: 30103096
[TBL] [Abstract][Full Text] [Related]
14. Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer.
Arrieta O; Angulo LP; Núñez-Valencia C; Dorantes-Gallareta Y; Macedo EO; Martínez-López D; Alvarado S; Corona-Cruz JF; Oñate-Ocaña LF
Ann Surg Oncol; 2013 Jun; 20(6):1941-8. PubMed ID: 23263699
[TBL] [Abstract][Full Text] [Related]
15. Health State Values Derived from People with Multiple Sclerosis for a Condition-Specific Preference-Based Measure: Multiple Sclerosis Impact Scale-Eight Dimensions-Patient Version (MSIS-8D-P).
Goodwin E; Green C; Hawton A
Value Health; 2018 Nov; 21(11):1338-1345. PubMed ID: 30442282
[TBL] [Abstract][Full Text] [Related]
16. Estimation of loss of quality-adjusted life expectancy (QALE) for patients with operable versus inoperable lung cancer: adjusting quality-of-life and lead-time bias for utility of surgery.
Yang SC; Lai WW; Chang HY; Su WC; Chen HH; Wang JD
Lung Cancer; 2014 Oct; 86(1):96-101. PubMed ID: 25178685
[TBL] [Abstract][Full Text] [Related]
17. A review and meta-analysis of utility values for lung cancer.
Sturza J
Med Decis Making; 2010; 30(6):685-93. PubMed ID: 20448248
[TBL] [Abstract][Full Text] [Related]
18. Health state utility scores in advanced non-small cell lung cancer.
Doyle S; Lloyd A; Walker M
Lung Cancer; 2008 Dec; 62(3):374-80. PubMed ID: 18467000
[TBL] [Abstract][Full Text] [Related]
19. Preferences for health outcomes and cost-utility analysis.
Torrance GW
Am J Manag Care; 1997 May; 3 Suppl():S8-20. PubMed ID: 10180342
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes.
Goeree R; Villeneuve J; Goeree J; Penrod JR; Orsini L; Tahami Monfared AA
J Med Econ; 2016 Jun; 19(6):630-44. PubMed ID: 26850122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
